Is Utah Medical Products, Inc. (UTMD) Overvalued?
We dive into why Utah Medical Products, Inc. (UTMD) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
Tudor Pop
| Share Statistics | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $237.8 | $391.4 | 30% |
|
| Shares Out (Mil) | 3.2 | 40.9 | 11% |
|
| Institutional Ownership | 90.7% | 83.6% | 59% |
|
| Float (Mil) | 2.8 | 35.5 | 7% |
|
| Beta | 0.36 | 0.85 | 21% |
|
| Avg Daily Volume (000s) | 44 | 288 | 27% |
|
| Price Change (52-week) |
24.3% | 61.7% | 72% |
|
| Growth | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (1.8%) | 11.8% | 14% |
|
| Net Income (5yr) | 0.9% | (5.5%) | 41% |
|
| EPS (5yr) | 3.4% | 10.6% | 36 |
|
| Dividends (5yr) | 1.8% | 0.0% | 83% |
|
| Cash Flow (5yr) | (18.6%) | (15.5%) | 37% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $36 | $141 | 17% |
|
| Net Income (TTM) (Mil) | $11 | ($9) | 46% |
|
| EPS (TTM) | $3.284 | ($0.400) | 79% |
|
| Operating Cash Flow (TTM) (Mil) | $12 | ($2) | 39% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $1 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $27 | 12% |
|
| Enterprise Value (Q1) (Mil) | $141 | $418 | 24% |
|
| Valuation | UTMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.95 | 2.51 | 53% |
|
| P/E | 22.8 | 25.9 | 60% |
|
| Dividend Yield | 1.7% | 0.0% | 73% |
|
| PEG (5yr hist) | 6.7 | 1.4 | 91% |
|
| Ratios | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 57.9% | 58.7% | 70% |
|
| Net Margin | 29.0% | (6.9%) | 87% |
|
| ROA | 8.5% | (12.2%) | 84% |
|
| ROE | 8.8% | (10.7%) | 53% |
|
| Liabilities to Assets | 2.0% | 47.2% | 1% |
|
| F-Score | 7 | 4 | 82% |
|
Passing Stock Screens
As of 10/19/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 6.5% |
| +/- S&P 500: | -1.0 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors